Knife wielding radiologist: A case report of primary pancreatic lymphoma

Cagle, Bradley A.; Holbert, Brenda L.; Wolanin, Stephanie; Tappouni, Rafel; Lalwani, Neeraj

doi:10.1016/j.ejro.2018.08.007

Cited by 5 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These treatments are generally administered in six courses. The second-line rituximab, isocyclophosphamide, carboplatin, and etoposide regimen or the rituximab, dexamethasone, high-dose cytarabine, and cisplatin (5) regimen can improve the prognosis of patients with refractory pancreatic DLBCL (4,5). Due to the large size of the tumor and the high risk of postoperative pancreatic fistula, surgical intervention is not the main treatment option for PPL (13).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pancreatic diffuse large B-cell lymphoma: a case report and literature review

Shi,

Wang,

Wei

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Primary pancreatic lymphoma is an extremely rare malignant tumor that accounts for 1% and 0.5% of all extranodal malignant lymphomas and pancreatic tumors, respectively. The clinical and radiographic characteristics of primary pancreatic lymphoma are non-specific, and it is often misdiagnosed as pancreatic cancer or pancreatic tuberculosis, delaying treatment. The most common histological subtype of primary pancreatic lymphoma is diffuse large B-cell lymphoma. Herein, we report a case of a 48-year-old female patient who was hospitalized for complaints of lower back pain, jaundice, dark brown urine, nausea, and ascites. Radiological evaluation revealed a pancreatic head mass that was diagnosed as diffuse large B-cell lymphoma following ultrasound-guided percutaneous fine-needle biopsy. During hospitalization, the patient’s jaundice worsened, and percutaneous transhepatic drainage was performed. However, hemorrhagic ascites and disorders of consciousness occurred after surgery, and the patient died due to multiple organ failure. Considering the outcome of this case, we reviewed the existing relevant literature on primary pancreatic lymphoma to better understand the disease to facilitate timely diagnosis and initiation of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Diffuse large B-cell lymphoma (DLBCL) is the most common (77%-80%) histological subtype of PPL (3,4). The treatment strategies for PPL include surgery, chemotherapy, radiotherapy, or comprehensive treatment; however, chemotherapy remains the standard treatment option.…”

Section: Introductionmentioning

confidence: 99%

Pancreatic diffuse large B-cell lymphoma: a case report and literature review

Shi,

Wang,

Wei

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Therefore, a clear diagnosis is crucial. In contrast to adenocarcinoma, PPL frequently manifests as a pancreatic tumor greater than 5 cm in length without evidence of vascular involvement[ 13 - 15 ]. No prior reports of PPL involving the PTCL-NOS exist.…”

Section: Introductionmentioning

confidence: 99%

Primary pancreatic peripheral T-cell lymphoma: A case report

Bai,

Wang,

Luo

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND Primary pancreatic lymphoma (PPL) is an exceedingly rare tumor with limited mention in scientific literature. The clinical manifestations of PPL are often nonspecific, making it challenging to distinguish this disease from other pancreatic-related diseases. Chemotherapy remains the primary treatment for these individuals. CASE SUMMARY In this case study, we present the clinical details of a 62-year-old woman who initially presented with vomiting, abdominal pain, and dorsal pain. On further evaluation through positron emission tomography-computed tomography, the patient was considered to have a pancreatic head mass. However, subsequent endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) revealed that the patient had pancreatic peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). There was a substantial decrease in the size of the pancreatic mass after the patient underwent a cycle of chemotherapy comprised of brentuximab vedotin, decitabine, and oxaliplatin (brentuximab vedotin and Gemox). The patient had significant improvement in radiological findings at the end of the first cycle. CONCLUSION Primary pancreatic PTCL-NOS is a malignant and heterogeneous lymphoma, in which the clinical manifestations are often nonspecific. It is difficult to diagnose, and the prognosis is poor. Imaging can only be used for auxiliary diagnosis of other diseases. With the help of immunostaining, EUS-FNA could be used to aid in the diagnosis of PPL. After a clear diagnosis, chemotherapy is still the first-line treatment for such patients, and surgical resection is not recommended. A large number of recent studies have shown that the CD30 antibody drug has potential as a therapy for several types of lymphoma. However, identifying new CD30-targeted therapies for different types of lymphoma is urgently needed. In the future, further research on antitumor therapy should be carried out to improve the survival prognosis of such patients.

show abstract